Phase 1 N=32 High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
Melanoma
Primary: Area Under the Curve (AUC) of PEG-Intron at 12 Weeks — 235000 pg*hr/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=22 Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
Carcinoma
Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…
Phase 1 N=24 Opioid and Cannabinoid Pharmacokinetic Interactions
Pain
Primary: Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use — 1.64; -1.11; 0.9; 0.99 Geometric Mean Ratio
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 1 N=26 Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 265.96; 260.04 ng/ml
Phase 1 N=26 Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Progressive Metastatic Malignancies
Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events
Phase 1 N=56 Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
Helminthiasis
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] of Albendazole. — 54.82; 48.07 nanogram (ng).hr per milliliter (mL)
Phase 1 N=45 Safety of Lactobacillus Reuteri in Healthy Volunteers
Healthy
Primary: Number of Participants With a Positive Blood Culture for L. Reuteri — 0; 0 participants
Phase 1 N=12 Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM) — 106.3; 122.6 mg/dL — p=0.024
Phase 1 N=21 Vitamin D Supplementation in Crohn's Patients
Inflammatory Bowel Disease
Primary: Crohn's Disease Activity Index — 230; 112 units on a scale
Phase 1 N=10 Safety of Polyphenon E in Multiple Sclerosis Pilot Study
Multiple Sclerosis
Primary: Number of Participants Experiencing Serious Adverse Events — 0 participants
Phase 1 N=30 Pilot Clinical Trial of Computer-based Motivational Intervention - 1
Substance-Related Disorders
Primary: Motivation to Change Substance Use — 88.8; 77.4 units on a scale
Phase 1 N=12 Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
HIV
Primary: Median Scores on a Subjective Sweet Intensity Scale for Current and New Powder for Oral Use (POU) Formulations of Atazanavir — 1.5; 1.5; 1.0 Units on a scale
Phase 1 N=20 A Smoking Cessation Treatment for Adult Women
Nicotine Dependence
Primary: Point-prevalence Smoking Abstinence Assessed at the End of the Trial and Measured by Self-report and Confirmed by Carbon Monoxide Levels — 4; 1 participants
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants